CenterBook Partners LP Has $3.60 Million Position in GH Research PLC $GHRS

CenterBook Partners LP increased its position in shares of GH Research PLC (NASDAQ:GHRS) by 70.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 283,441 shares of the company’s stock after purchasing an additional 117,288 shares during the quarter. CenterBook Partners LP’s holdings in GH Research were worth $3,600,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research during the 4th quarter worth approximately $38,000. Osaic Holdings Inc. lifted its holdings in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in GH Research during the 2nd quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new stake in GH Research during the 4th quarter worth approximately $128,000. Finally, BNP Paribas Financial Markets lifted its holdings in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after purchasing an additional 10,600 shares during the last quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GHRS has been the subject of several research reports. HC Wainwright dropped their price target on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Citigroup reissued an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Guggenheim set a $34.00 price target on GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a report on Tuesday, April 21st. Finally, Citizens Jmp dropped their price target on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, May 15th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.38.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $20.12 on Tuesday. The stock has a market capitalization of $1.38 billion, a PE ratio of -21.87 and a beta of 1.31. The business has a fifty day moving average price of $19.66 and a two-hundred day moving average price of $16.54. GH Research PLC has a fifty-two week low of $11.32 and a fifty-two week high of $25.94.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, equities analysts expect that GH Research PLC will post -1.46 EPS for the current year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.